AAD 2025: Lebrikizumab Effective in Atopic Dermatitis for Up to 3 Years

Use of lebrikizumab (Ebglyss) can effectively treat atopic dermatitis for up to 3 years, according to data from the ADjoin trial.

A targeted IL-13 inhibitor from Eli Lilly and Company, results of the study, which were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, underline the long-term efficacy of lebrikizumab in patients with atopic dermatitis.

"Healthcare providers are constantly searching for ways to help patients achieve deep, sustainable improvement in the signs and symptoms of their atopic dermatitis," said Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research.2 "These three-year data show that raising the bar in atopic dermatitis treatment to long-term total skin clearance was an achievable treatment goal for at least half of [lebrikizumab] Week 16 responders, reinforcing its efficacy as a first-line biologic treatment for people with moderate-to-severe atopic dermatitis uncontrolled by topicals."

Lebrikizumab received US Food and Drug Administration (FDA) approval in September 2024 in adults and children 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies based on data from the ADvocate 1, ADvocate 2, and ADhere studies.3

As part of the clinical development program, Eli Lilly and Company launched the ADjoin study in June 2020. A 321-site, open-label study, ADjoin included patients who had completed participation in ADvocate 1 and 2 monotherapy trials, ADhere, ADore, or ADopt-VA as well as approximately 100 patients in the US who had not completed participation in a sponsored lebrikizumab trial.1

In the 100-week ADjoin data from AAD 2025, results indicated IGA 0 was reported for 63.4% of patients receiving lebrikizumab once every 2 weeks and 50.0% of those receiving lebrikizumab once every 4 weeks. Investigators noted EASI 90 was achieved by EASI 90 was reported for 79.4% of patients receiving lebrikizumab once every 2 weeks and 86.8% of those receiving lebrikizumab once every 4 weeks. Further analysis suggested EASI 100 was achieved by 49.2% of those receiving lebrikizumab once every 2 weeks and 50.0% of those receiving lebrikizumab once every 4 weeks.1

"We hear from patients with moderate-to-severe atopic dermatitis that they struggle with recurring and unpredictable flares and are looking for treatment options that can provide long-term disease control," said Mark Genovese, MD, senior vice president of Eli Lilly and Company Immunology development.1 "[Lebrikizumab] is the only first-line biologic treatment option for patients with disease uncontrolled by topicals to report completely clear skin at three years with a once-monthly maintenance dose. The additional assessments presented at AAD demonstrate significant improvements in disruptive symptoms, such as itch, across a range of patient groups."

In addition to this study from AAD 2025, a release from Eli Lilly and Company also highlighted data from the ADmirable and ADapt trials. In ADmirable, a study for people with skin of color and moderate-to-severe atopic dermatitis, more than 30% of patients saw a reduction in sleep loss due to itch at Week 16. In ADapt, a study of patients who were previously treated with dupilumab, 75% achieved significant improvement in skin pain and 62% achieved significant improvement in itch at week 24.2

References:

1. Eric Simpson, Tilo Biedermann T, Kircik L, et al. Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Maintains Depth of Response Over 3 Years in Week 16 Responders. Presented at the 2025 American Academy of Dermatology (ADA) Annual Meeting. Orlando, FL. March 07-11, 2025.

2. Eli Lilly and Company. Lilly’s EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis. Eli Lilly and Company. March 7, 2025. Accessed March 7, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-ebglyssr-lebrikizumab-lbkz-single-monthly-maintenance.

3. ClinicalTrials.gov. Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin). Clinicaltrials.gov. February 27, 2025. Accessed March 7, 2025. https://clinicaltrials.gov/study/NCT04392154.